WO2006040318A3 - Pi3 kinase gamma inhibitors for the treatment of anaemia - Google Patents

Pi3 kinase gamma inhibitors for the treatment of anaemia Download PDF

Info

Publication number
WO2006040318A3
WO2006040318A3 PCT/EP2005/055156 EP2005055156W WO2006040318A3 WO 2006040318 A3 WO2006040318 A3 WO 2006040318A3 EP 2005055156 W EP2005055156 W EP 2005055156W WO 2006040318 A3 WO2006040318 A3 WO 2006040318A3
Authority
WO
WIPO (PCT)
Prior art keywords
anaemia
treatment
gamma inhibitors
kinase gamma
selective
Prior art date
Application number
PCT/EP2005/055156
Other languages
French (fr)
Other versions
WO2006040318A2 (en
Inventor
Reinhard Wetzker
Angelika Mueller
Christian Rommel
Original Assignee
Applied Research Systems
Reinhard Wetzker
Angelika Mueller
Christian Rommel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200700848A priority Critical patent/EA200700848A1/en
Priority to AU2005293556A priority patent/AU2005293556A1/en
Priority to US11/664,969 priority patent/US20090042773A1/en
Priority to MX2007004302A priority patent/MX2007004302A/en
Priority to CA002580480A priority patent/CA2580480A1/en
Priority to BRPI0517416-3A priority patent/BRPI0517416A/en
Application filed by Applied Research Systems, Reinhard Wetzker, Angelika Mueller, Christian Rommel filed Critical Applied Research Systems
Priority to EP05801722A priority patent/EP1807075A2/en
Priority to JP2007536166A priority patent/JP2008515955A/en
Publication of WO2006040318A2 publication Critical patent/WO2006040318A2/en
Publication of WO2006040318A3 publication Critical patent/WO2006040318A3/en
Priority to IL182110A priority patent/IL182110A0/en
Priority to NO20072393A priority patent/NO20072393L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This present invention is related to the use of selective PI3 Kinase gamma inhibitors for the manufacture of a medicament for the treatment of disorders related to erythrocyte deficiency. Specifically, the present invention is related to the use of selective PI3 Kinase gamma inhibitors, e.g. substituted azolidinone-vinyl fused-benzene derivatives of formula I wherein A, X, Y1, Y2, Z, n, R1 and R2 are described in details in the description hereinafter for the treatment of an anaemia, including haemolytic anaemia, aplastic anaemia and pure red cell anaemia.
PCT/EP2005/055156 2004-10-12 2005-10-11 Pi3 kinase gamma inhibitors for the treatment of anaemia WO2006040318A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2005293556A AU2005293556A1 (en) 2004-10-12 2005-10-11 PI3 Kinase gamma inhibitors for the treatment of anaemia
US11/664,969 US20090042773A1 (en) 2004-10-12 2005-10-11 P13 kinase gamma inhibitors for the treatment of anaemia
MX2007004302A MX2007004302A (en) 2004-10-12 2005-10-11 Pi3 kinase gamma inhibitors for the treatment of anaemia.
CA002580480A CA2580480A1 (en) 2004-10-12 2005-10-11 Pi3 kinase gamma inhibitors for the treatment of anaemia
BRPI0517416-3A BRPI0517416A (en) 2004-10-12 2005-10-11 gamma pi3 kinase inhibitors for treatment of anemia
EA200700848A EA200700848A1 (en) 2004-10-12 2005-10-11 PI3-GAMMA KINASE INHIBITORS FOR THE TREATMENT OF ANEMIA
EP05801722A EP1807075A2 (en) 2004-10-12 2005-10-11 Pi3 kinase gamma inhibitors for the treatment of anaemia
JP2007536166A JP2008515955A (en) 2004-10-12 2005-10-11 PI3 kinase gamma inhibitor for the treatment of anemia
IL182110A IL182110A0 (en) 2004-10-12 2007-03-22 P13 kinase gamma inhibitors for the treatment of anemia
NO20072393A NO20072393L (en) 2004-10-12 2007-05-09 P13-kinase gamma inhibitors for the treatment of anemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104997.4 2004-10-12
EP04104997 2004-10-12

Publications (2)

Publication Number Publication Date
WO2006040318A2 WO2006040318A2 (en) 2006-04-20
WO2006040318A3 true WO2006040318A3 (en) 2006-08-10

Family

ID=34929693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/055156 WO2006040318A2 (en) 2004-10-12 2005-10-11 Pi3 kinase gamma inhibitors for the treatment of anaemia

Country Status (14)

Country Link
US (1) US20090042773A1 (en)
EP (1) EP1807075A2 (en)
JP (1) JP2008515955A (en)
KR (1) KR20070073857A (en)
CN (1) CN101056633A (en)
AU (1) AU2005293556A1 (en)
BR (1) BRPI0517416A (en)
CA (1) CA2580480A1 (en)
EA (1) EA200700848A1 (en)
IL (1) IL182110A0 (en)
MX (1) MX2007004302A (en)
NO (1) NO20072393L (en)
WO (1) WO2006040318A2 (en)
ZA (1) ZA200702435B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200701666B (en) * 2004-09-03 2008-07-30 Laboratroires Serono Sa Pyridine méthylène azolidinones and use thereof phospho-inositide inhibitors
EP2046333A4 (en) * 2006-07-24 2010-09-15 Glaxosmithkline Llc Thiozolidinedione derivatives as p13 kinase inhibitors
JP5561702B2 (en) 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド PI3 kinase modulator and method of use
PE20091268A1 (en) 2007-12-19 2009-09-19 Amgen Inc HETEROCYCLIC DERIVATIVES AS PI3 KINASE INHIBITORS
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
WO2010110380A1 (en) * 2009-03-27 2010-09-30 興和株式会社 Fused piperidine compound and pharmaceutical agent comprising same
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
US8633183B2 (en) * 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102584809B (en) * 2011-01-14 2014-12-24 湘北威尔曼制药股份有限公司 Amion thiazolidone compound, method for preparing same and application thereof in preparing antitumor drugs
US8901145B2 (en) 2011-04-22 2014-12-02 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
JP6215832B2 (en) 2011-11-04 2017-10-18 ジャスコ ファーマスーティカルズ エルエルシーＪａｓｃｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， ＬＬＣ Aminopyrimidine kinase inhibitor
CR20200286A (en) * 2011-12-22 2020-09-23 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
WO2015162456A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US10004732B2 (en) 2014-04-24 2018-06-26 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016013983A (en) 2014-04-24 2017-04-06 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors.
EA202092490A1 (en) 2018-04-18 2020-12-23 Констеллейшен Фармасьютикалс, Инк. METHYL-MODIFYING ENZYMES MODULATORS, COMPOSITIONS AND THEIR APPLICATION
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JPWO2022163843A1 (en) * 2021-02-01 2022-08-04

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047760A2 (en) * 2002-11-22 2004-06-10 Smithkline Beecham Corporation Novel chemical compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
BR0312752A (en) * 2002-07-10 2005-04-26 Applied Research Systems Azolidinone-vinyl fused benzene derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047760A2 (en) * 2002-11-22 2004-06-10 Smithkline Beecham Corporation Novel chemical compounds

Also Published As

Publication number Publication date
KR20070073857A (en) 2007-07-10
MX2007004302A (en) 2007-06-07
EA200700848A1 (en) 2007-10-26
CA2580480A1 (en) 2006-04-20
AU2005293556A1 (en) 2006-04-20
JP2008515955A (en) 2008-05-15
CN101056633A (en) 2007-10-17
WO2006040318A2 (en) 2006-04-20
ZA200702435B (en) 2008-06-25
US20090042773A1 (en) 2009-02-12
IL182110A0 (en) 2007-07-24
EP1807075A2 (en) 2007-07-18
BRPI0517416A (en) 2008-10-07
NO20072393L (en) 2007-05-09

Similar Documents

Publication Publication Date Title
WO2006040318A3 (en) Pi3 kinase gamma inhibitors for the treatment of anaemia
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
WO2006021884A3 (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
TW200833324A (en) Sulfonamide derivatives
WO2006005609A3 (en) Substituted oxindol derivatives and medicaments containing the same
WO2005118557A3 (en) Heterocyclic compounds and their use as aldosterone synthase inhibitors
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
NO20071593L (en) pyrimidine
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
WO2008017932A3 (en) Heterocycles useful as inhibitors of carbonic anhydrase
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
UA94065C2 (en) Dihydropseudoerythromycin derivatives
WO2006005726A3 (en) Heterocyclic compounds
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2005118541A3 (en) Heterocyclic compounds and their use as aldosterone synthase inhibitors
WO2006116733A3 (en) Protein kinase inhibitors
WO2006000371A3 (en) Pyrimidine derivatives as 11beta-hsd1 inhibitors
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2007068728A3 (en) N-substituted pyrrolopyridinones active as kinase inhibitors
UA86776C2 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
MXPA05013050A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2580480

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005293556

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 182110

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007/02435

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2450/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005801722

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/004302

Country of ref document: MX

Ref document number: 2007536166

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005293556

Country of ref document: AU

Date of ref document: 20051011

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005293556

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077010007

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580038804.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200700848

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 11664969

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005801722

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0517416

Country of ref document: BR